Roche's Hemlibra and Alnylam's late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ...
Roche's Hemlibra and Alnylam's late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ...
No comments:
Post a Comment